Primary analysis of the ROSEWOOD trial – zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).
Factsheet describing the long-term follow-up of the ASPEN trial -zanubrutinib vs ibrutinib in Waldenström’s macroglobulinemia (WM) patients.
ASPEN is an open-label, randomized, Phase 3 study comparing the safety, efficacy and clinical benefit of zanubrutinib
BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to fight cancer. Get up-to-date with the BeiGene hematology pipeline and clinical trials.
A summary of the latest developments from 12 studies in BTK inhibition in B-cell malignancies presented at EHA2022.
